Evidence map›Paper›PMID 40458721›Full record

ArticleFrontiers in oncology2025

Integrating next-generation sequencing and artificial intelligence for the identification and validation of pathogenic variants in colorectal cancer.

Juliana Rodriguez-Salamanca, Mariana Angulo-Aguado, Sarah Orjuela-Amarillo, Catalina Duque, Diana Carolina Sierra-Díaz, Nora Contreras Bravo, Carlos Figueroa, Carlos M Restrepo, Andrés López-Cortés, Rodrigo Cabrera and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Juliana Rodriguez-SalamancaSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Mariana Angulo-AguadoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Sarah Orjuela-AmarilloSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Catalina DuqueSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Diana Carolina Sierra-DíazSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Nora Contreras BravoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Carlos FigueroaColoproctology Department, Hospital Universitario Mayor - Méderi - Universidad del Rosario, Bogotá, Colombia.
Carlos M RestrepoSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Andrés López-CortésCancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador.
Rodrigo CabreraSchool of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Adrien Morel *School of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.
Dora Janeth Fonseca-Mendoza *School of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Universidad del Rosario, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is recognized as a multifactorial disease, where both genetic and environmental factors play critical roles in its development and progression. The identification of pathogenic germline variants has proven to be a valuable tool for early diagnosis, the implementation of surveillance strategies, and the identification of individuals at increased cancer risk. Next-generation sequencing (NGS) has facilitated comprehensive multigene analysis in both hereditary and sporadic cases of CRC. Patients and methods: In this study, we analyzed 100 unselected Colombian patients with CRC to identify pathogenic (P) and likely pathogenic (LP) germline variants, classified according to the guidelines established by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP). Using the BoostDM artificial intelligence method, we were able to identify oncodriver germline variants with potential implications for disease progression. We assessed the model's accuracy in predicting germline variants by comparing its results with the AlphaMissense pathogenicity prediction model. Additionally, a minigene assay was employed for the functional validation of intronic mutations. Results: Our findings revealed that 12% of the patients carried pathogenic/likely pathogenic (P/LP) variants according to ACMG/AMP criteria. Using BoostDM, we identified oncodriver variants in 65% of the cases. These results highlight the significance of expanded multigene analysis and the integration of artificial intelligence in detecting germline variants associated with CRC. The average overall AUC values for the comparison between BoostDM and AlphaMissense were 0.788 for the entire BoostDM dataset and 0.803 for the genes within our panel, with individual gene AUC values ranging from 0.606 to 0.983. Functional validation through the minigene assay revealed the generation of aberrant transcripts, potentially linked to the molecular etiology of the disease. Conclusion: Our study provided valuable insights into the prevalence and frequency of P/LP germline variants in unselected Colombian CRC patients through NGS. Integrating advanced genomic analysis and artificial intelligence has proven instrumental in enhancing variant detection beyond conventional methods. Our functional validation results provide insights into the potential pathogenicity of intronic variants. These findings underscore the necessity of a multifaceted approach to unravel the complex genetic landscape of CRC.

Indexed as

artificial intelligencecolorectal cancerfunctional validationminigene assaynext generation sequencing (NGS)pathogenic germline variants

Identifiers

PMID40458721
PMCPMC12127813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.